Yong M, Wu YQ, Howlett J, et al. - Researchers conducted the study for comparing the cost-effectiveness of acetylsalicyclic acid desensitization with dupilumab therapy for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in aspirin-exacerbated respiratory disease. Cost-effectiveness [measured in quality-adjusted life years], and cost-utility [measured in the number of required revision endoscopic sinus surgeries] analyses were performed. Under the willingness-to-pay threshold of $150,000, dupilumab for the treatment of severe CRSwNP was found to be cost-effective as salvage therapy. Further research revealed that the cost-effectiveness of dupilumab was most sensitive to drug price and expected quality-of-life gains. This implies that further research into improving patient population selection and tailoring treatment algorithms could improve the cost-effectiveness of dupilumab in specific scenarios.